Barbara Ressler, Ph.D.

Dr. Ressler is responsible for managing the Analytical Development, Process Development, and Manufacturing Sciences & Technology (MS&T) teams. The mission of these teams is to create robust, GMP-compliant processes and assays for RoslinCT’s partners, and to facilitate transfer to Manufacturing and QC.

Prior to her role as Vice President of Manufacturing Process Sciences at RoslinCT USA (formerly Lykan Bioscience), she was Senior Director of Process Development at Mustang Bio, and Director of Cell Manufacturing at Editas Medicine.  She has helped move several cell and gene therapy (CGT) products into the clinic and has contributed to three licensed CGT products, including a recently successful biologics license application for RETHYMIC®.  Dr. Ressler is passionate about completing the monumental work required to bring life-saving CGT products to market.  She strives to build quality data sets that can be used to drive decisions and deepen our understanding of our partners’ products and processes.

Dr. Ressler started working in the CGT industry when there was only one FDA-approved product, and she looks forward to being involved in several more approvals as the industry grows.  She has a B.S. in biomedical engineering from Northwestern University and an S.M. and Ph.D. in mechanical engineering from the Massachusetts Institute of Technology.